Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTSO NASDAQ:LFWD NASDAQ:NMTC NASDAQ:PSTV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTSOCytosorbents$0.61+0.6%$0.66$0.50▼$1.39$38.18M1.4377,173 shs18,025 shsLFWDLifeward$6.82-2.6%$6.68$4.14▼$17.76$10.44M0.3220,644 shs2,982 shsNMTCNeuroOne Medical Technologies$4.31-2.6%$4.52$3.27▼$6.96$36.32M0.643,991 shs38,774 shsPSTVPlus Therapeutics$6.01-3.4%$6.09$2.90▼$23.42$40.99M1.4429,525 shs92,903 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTSOCytosorbents-1.50%+0.85%+3.79%-9.85%-33.35%LFWDLifeward-3.31%-1.27%+2.04%+3.56%-58.03%NMTCNeuroOne Medical Technologies+1.84%-6.74%-7.13%-7.96%+15.84%PSTVPlus Therapeutics+2.13%+4.54%+74.72%+2.77%-59.89%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTSOCytosorbents$0.61+0.6%$0.66$0.50▼$1.39$38.18M1.4377,173 shs18,025 shsLFWDLifeward$6.82-2.6%$6.68$4.14▼$17.76$10.44M0.3220,644 shs2,982 shsNMTCNeuroOne Medical Technologies$4.31-2.6%$4.52$3.27▼$6.96$36.32M0.643,991 shs38,774 shsPSTVPlus Therapeutics$6.01-3.4%$6.09$2.90▼$23.42$40.99M1.4429,525 shs92,903 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTSOCytosorbents-1.50%+0.85%+3.79%-9.85%-33.35%LFWDLifeward-3.31%-1.27%+2.04%+3.56%-58.03%NMTCNeuroOne Medical Technologies+1.84%-6.74%-7.13%-7.96%+15.84%PSTVPlus Therapeutics+2.13%+4.54%+74.72%+2.77%-59.89%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTSOCytosorbents 2.00Hold$5.38782.59% UpsideLFWDLifeward 2.00Hold$10.0046.63% UpsideNMTCNeuroOne Medical Technologies 2.25Hold$13.50212.93% UpsidePSTVPlus Therapeutics 2.43Hold$58.00865.06% UpsideCurrent Analyst Ratings BreakdownLatest LFWD, PSTV, NMTC, and CTSO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026LFWDLifeward Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026PSTVPlus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/9/2026PSTVPlus Therapeutics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$475.00 ➝ $65.004/8/2026CTSOCytosorbents Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/31/2026PSTVPlus Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold3/26/2026CTSOCytosorbents D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.003/19/2026LFWDLifeward HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.003/19/2026PSTVPlus Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$75.003/13/2026NMTCNeuroOne Medical Technologies Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/2/2026NMTCNeuroOne Medical Technologies JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$9.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTSOCytosorbents$37.06M1.03N/AN/A$0.09 per share6.77LFWDLifeward$22.03M0.47N/AN/A$5.52 per share1.24NMTCNeuroOne Medical Technologies$12.10M3.00N/AN/A$0.85 per share5.08PSTVPlus Therapeutics$5.21M7.91N/AN/A$0.72 per share8.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTSOCytosorbents-$8.20M-$0.13N/AN/AN/A-22.12%-150.53%-32.75%5/13/2026 (Estimated)LFWDLifeward-$19.91M-$18.49N/AN/AN/A-90.38%-145.55%-78.36%5/7/2026 (Estimated)NMTCNeuroOne Medical Technologies-$3.61M-$1.02N/AN/AN/A-78.34%-119.92%-78.86%5/12/2026 (Estimated)PSTVPlus Therapeutics-$22.39M-$31.00N/AN/AN/A-429.43%N/A-92.28%5/29/2026 (Estimated)Latest LFWD, PSTV, NMTC, and CTSO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2026Q1 2026PSTVPlus Therapeutics-$0.8460N/AN/AN/A$0.97 millionN/A5/21/2026Q1 2026LFWDLifeward-$1.18N/AN/AN/A$5.78 millionN/A5/13/2026Q1 2026CTSOCytosorbents-$0.06N/AN/AN/A$9.40 millionN/A5/12/2026Q2 2026NMTCNeuroOne Medical Technologies-$0.2267N/AN/AN/A$2.58 millionN/A3/25/2026Q4 2025CTSOCytosorbents-$0.05-$0.09-$0.04-$0.09$9.22 million$9.23 million3/19/2026Q4 2025LFWDLifeward-$0.07-$3.60-$3.53-$3.60$7.87 million$5.08 million3/12/2026Q4 2025PSTVPlus Therapeutics-$0.03$6.25+$6.28N/A$1.23 million$1.37 million2/17/2026Q1 2026NMTCNeuroOne Medical Technologies-$0.24-$0.18+$0.06-$0.03$2.47 million$2.89 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCTSOCytosorbentsN/AN/AN/AN/AN/ALFWDLifewardN/AN/AN/AN/AN/ANMTCNeuroOne Medical TechnologiesN/AN/AN/AN/AN/APSTVPlus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTSOCytosorbents2.822.131.58LFWDLifewardN/A1.310.84NMTCNeuroOne Medical TechnologiesN/A6.415.09PSTVPlus TherapeuticsN/A1.231.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTSOCytosorbents32.87%LFWDLifeward26.76%NMTCNeuroOne Medical Technologies16.07%PSTVPlus Therapeutics3.28%Insider OwnershipCompanyInsider OwnershipCTSOCytosorbents6.60%LFWDLifeward1.50%NMTCNeuroOne Medical Technologies11.80%PSTVPlus Therapeutics2.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTSOCytosorbents22062.70 million58.56 millionOptionableLFWDLifeward601.53 million1.51 millionOptionableNMTCNeuroOne Medical Technologies208.42 million7.43 millionOptionablePSTVPlus Therapeutics206.86 million6.69 millionNot OptionableLFWD, PSTV, NMTC, and CTSO HeadlinesRecent News About These CompaniesPlus Therapeutics (PSTV) price target decreased by 72.34% to 38.76April 29, 2026 | msn.comPlus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS CancerApril 28, 2026 | globenewswire.comPlus Therapeutics Inc.: Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQApril 24, 2026 | finanznachrichten.dePlus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™April 23, 2026 | globenewswire.comPlus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)April 22, 2026 | globenewswire.comPlus Therapeutics Regains Nasdaq Listing Compliance After Reverse SplitApril 22, 2026 | theglobeandmail.comPlus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementApril 21, 2026 | globenewswire.comPlus Therapeutics Enacts Reverse Stock Split to Maintain ListingApril 17, 2026 | theglobeandmail.comPlus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial ExecutionApril 15, 2026 | globenewswire.comPSTV stock on track for best week since September — here’s what is driving the rallyApril 10, 2026 | msn.comPlus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical PipelineApril 9, 2026 | markets.businessinsider.comPlus Therapeutics (PSTV) price target increased by 2,400.00% to 145.35April 9, 2026 | msn.comPlus Therapeutics Appoints Eric J. Daniels, M.D.April 9, 2026 | globenewswire.comPlus Therapeutics stock gains after FDA orphan drug nodApril 8, 2026 | in.investing.comPlus Therapeutics secures FDA orphan drug status for pediatric glioma treatmentApril 8, 2026 | msn.comPlus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant GliomasApril 8, 2026 | globenewswire.comPlus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing ...April 7, 2026 | bakersfield.comBPlus Therapeutics (PSTV) Stock: CNSide Diagnostic Secures AMA Billing Code Despite Share DeclineApril 7, 2026 | blockonomi.comD. Boral Capital Downgrades Plus Therapeutics (PSTV) to HoldApril 7, 2026 | finance.yahoo.comPlus Therapeutics, Inc. Secures Proprietary CPT Code 0640U for CNSide CSF Tumor Cell Enumeration TestApril 7, 2026 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLFWD, PSTV, NMTC, and CTSO Company DescriptionsCytosorbents NASDAQ:CTSO$0.61 +0.00 (+0.64%) As of 11:59 AM Eastern This is a fair market value price provided by Massive. Learn more.Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.Lifeward NASDAQ:LFWD$6.82 -0.18 (-2.57%) As of 11:58 AM Eastern This is a fair market value price provided by Massive. Learn more.ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.NeuroOne Medical Technologies NASDAQ:NMTC$4.31 -0.12 (-2.62%) As of 12:00 PM Eastern This is a fair market value price provided by Massive. Learn more.NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.Plus Therapeutics NASDAQ:PSTV$6.01 -0.21 (-3.38%) As of 12:00 PM Eastern This is a fair market value price provided by Massive. Learn more.Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
